Dubov A, Krakower DS, Rockwood N, Montgomery S, Shoptaw S. Provider implicit bias in prescribing HIV pre-exposure prophylaxis (PrEP) to people who inject drugs. J Gen Intern Med. 2023 Oct;38(13):2928-35. doi: 10.1007/s11606-023-08040-7
Mansfield C, Sutphin J, Boeri M. Assessing the impact of excluded attributes on choice in a discrete choice experiment using a follow-up question. Health Econ. 2020 Oct;29(10):1307-15. doi: 10.1002/hec.4124
Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093
Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037
Heidenreich S, Watson V, Ryan M, Phimister E. Decision heuristic or preference? Attribute non-attendance in discrete choice problems. Health Econ. 2018 Jan;27(1):157-71. doi: 10.1002/hec.3524
Tsuchiya A, Watson V. Re-thinking “the different perspectives that can be used when eliciting preferences in health". Health Econ. 2017 Dec;26(12):e103-7. doi: 10.1002/hec.3480
Krucien N, Watson V, Ryan M. Is best-worst scaling suitable for health state valuation? A comparison with discrete choice experiments. Health Econ. 2017 Dec;26(12):e1-e16. doi: 10.1002/hec.3459
Watson V, Becker F, de Bekker-Grob E. Discrete choice experiment response rates: a meta-analysis. Health Econ. 2017 Jun;26(6):810-7. doi: 10.1002/hec.3354
Mandl KD, Olson KL, Mines D, Liu C, Tian F. Provider collaboration: cohesion, constellations, and shared patients. J Gen Intern Med. 2014 Nov;29(11):1499-505. doi: 10.1007/s11606-014-2964-0
Rothman KJ. Six persistent research misconceptions. J Gen Intern Med. 2014 Jul;29(7):1060-4. doi: 10.1007/s11606-013-2755-z
Pignone M, Earnshaw S, McDade C, Pletcher MJ. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med. 2013 Oct;28(11):1483-91.
Zarkin GA, Cowell AJ, Hicks KA, Mills MJ, Belenko S, Dunlap LJ, Houser KA, Keyes V. Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model. Health Econ. 2012 Jun;21(6):633-52.
Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA. Toward development of a fibromyalgia responder index and disease activity score: oMERACT module update. J Rheumatol. 2011 Jul 1;38(7):1487-95.
Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009 Oct 1;36(10):2330-4.
Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009 Oct 1;36(10):2318-29.
Ryan M, Watson V. Comparing welfare estimates from payment card contingent valuation and discrete choice experiments. Health Econ. 2009 Apr;18(4):389-401. doi: 10.1002/hec.1364
Ryan M, Watson V, Entwistle V. Rationalising the 'irrational': a think aloud study of discrete choice experiment responses. Health Econ. 2009 Mar;18(3):321-36. doi: 10.1002/hec.1369
Candrilli SD, Kuznik A. The prevalence and overlap of select cardiovascular comorbidities among dyslipidemic US adults aged 65 years or older, stratified by lipid-lowering medication use. Poster presented at the 31st Annual Meeting of the Society of General Internal Medicine; April 2008. Pittsburg, PA. [abstract] J Gen Intern Med. 2008 Apr; 23(Supplement 2):419.
Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008 Mar;35(3):502-14.
Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin SA. OMERACT 8 workshop: fibromyalgia syndrome. J Rheumatol. 2007 Jun;34(6):1415-25.
Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005 Nov 1;14(11):1133-50.
Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.
Neville C, Whalley D, McKenna SP, Le Comte M, Fortin PR. Adaptation and validation of the Rheumatoid Arthritis Quality of Life Scale for use in Canada. J Rheumatol. 2001 Jul 1;28(7):1505-10.
Mines D, Fosnocht KM, Berlin JA, Strom BL. Can primary care physicians diagnose innocent heart murmurs? Presented at the 1999 22nd Annual Meeting of the Society for General Internal Medicine; May 1, 1999. San Francisco, CA. [abstract] J Gen Intern Med. 1999 Feb; 14(Suppl 2):113. doi: 10.1046/j.1525-1497.1999.1420005.x
Perez-Gutthann S, Petri M, Hochberg MC. Comparison of two methods of classifying patients with systemic lupus erythematosus. J Rheumatol. 1991 Aug 1;18(8):1176-9.